5、请问贵公司医疗器械方面与欧洲是否有进一步的合作。 回复：尊敬的投资者，您好！2024 年 10 月，公司董事长携医 疗团队赴瑞士与某 IVD 客户进行友好洽谈，就未来两年双方深 入合作开发的产品计划进行了深入沟通。初步就该客户推出的 全球十余款新品系列达成开发意向，并签署相关协议，其中部 分产品已取得相应订单。2025 年第一季度，该 IVD 客户贡献 营收较上年同期增长 90%左右，同时正在进一步讨论扩大未来 合作的渠道、领域及产品覆盖区域！敬请广大投资者注意投资 风险，感谢您对公司的关注！ 6、半导体耗材领域，是否已经在供货阶段？能对公司实质业 绩提供多大的支撑？贵司题材概念为何没有半导体？ 证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2025-001 | | □分析师会议 □媒体采访 □√ 业绩说明会 | □特定对象调研 | | --- | --- | --- | | 投资者关系活 | | | | | □新闻发布会 □路演活动 | | | 动类别 | □现场参观 | | | | □其他 | | ...

2025 年 5 月 7 日 公司研究 Q1 业绩表现亮眼，医疗和消费品板块协同发力 ——稳健医疗（300888.SZ）2024 年年报及 2025 年一季报点评 增持（维持） 当前价：52.22 元 作者 分析师：姜浩 执业证书编号：S0930522010001 021-52523680 jianghao@ebscn.com 分析师：孙未未 执业证书编号：S0930517080001 021-52523672 sunww@ebscn.com 分析师：朱洁宇 执业证书编号：S0930523070004 021-52523842 zhujieyu@ebscn.com | 市场数据 | | | --- | --- | | 总股本(亿股) | 5.82 | | 总市值(亿元)： | 304.09 | | 一年最低/最高(元)： | 22.99/54.80 | | 近 3 月换手率： | 61.74% | 股价相对走势 -30% -12% 6% 24% 42% 04/24 07/24 10/24 01/25 稳健医疗 沪深300 | 收益表现 | | | | | --- | --- | --- | --- | | % ...

【环球网科技报道 记者 张阳】近日，乐纯生物宣布其自主研发的Extreme™ PVDF除菌过滤膜取得重大突破，凭借高纯净度、高通量及低蛋白吸附三大核 心技术指标，实现了关键性能参数的国际领先水平，标志着中国本土生物工艺公司在保障供应链安全方面迈出了坚实的一步。 下游需求侧，供应链稳定促成国产自研机遇 面对全球供应链波动系数不断加大的挑战，乐纯生物深知源头研发能力的重要性。从2021年推出生物工艺薄膜Lekrius®膜到今年新推出的Extreme™ PVDF 滤膜，乐纯生物长期聚焦底层突破，在"双膜"（即film和membrane）材料科学源头构建技术护城河。 "夯实底层研发，才能支撑起应用产品研发的活跃度，形成门类齐全的自研产品矩阵，从而支撑起整个供应链的安全可控。"秦孙星强调。乐纯生物针对一 次性系统、细胞培养、过滤纯化三大类耗材，均采取了"攻坚底层研发、深耕应用研发、优化整体工艺"的策略，成功实现了旗下一次性配储液袋、生物反 应袋/生物反应器、细胞培养袋等产品的全国产化生产。 在过滤业务方面，随着PVDF滤膜自研并稳定量产，乐纯生物迅速推出了相应的除菌级、除病毒级过滤器产品，支持了不同领域的产品布局。公司 ...

Core Points - The China Securities Index for Hong Kong Stock Connect Medical Comprehensive Index reported a value of 1467.39 points, showing a monthly increase of 0.37%, a three-month increase of 10.32%, and a year-to-date increase of 11.90% [1] - The index is designed to reflect the overall performance of different industry securities within the Hong Kong Stock Connect, categorized according to the China Securities Industry Classification Standard [1] - The top ten weighted stocks in the index include JD Health (15.7%), Alibaba Health (15.39%), Sinopharm (11.5%), Weigao Group (7.35%), MicroPort Medical (4.9%), Ping An Good Doctor (4.63%), Shanghai Pharmaceuticals (3.7%), MicroPort Scientific-B (3.6%), Xianjian Technology (3.16%), and Jinxin Fertility (3.03%) [1] - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Industry Breakdown - The industry composition of the index shows that pharmaceutical commerce accounts for 48.51%, medical services for 23.49%, medical consumables for 23.03%, medical devices for 3.98%, and in vitro diagnostics for 0.98% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with provisions for temporary adjustments in case of special events affecting the index sample [2]

Core Insights - Nasda's revenue for Q1 2025 reached 5.927 billion yuan, with a net profit attributable to shareholders of 84 million yuan, and a net profit of 80 million yuan after deducting non-recurring gains and losses [1] - The company is focusing on enhancing its R&D, brand promotion, and offline service channels, which has led to increased expenses [1] - The company has seen growth in its key sectors, particularly in the domestic commercial market and the financial and government sectors [1][3] Business Segment Summary - **Printing Brand (Bentu)**: Revenue of 999.2 million yuan and a net profit of 97 million yuan. The brand has increased its market share in key industries, with a year-on-year sales growth of 11.24% in the trust and innovation market and 7.11% in the domestic commercial market [1] - **Lexmark**: Revenue of 513 million USD and a net profit of 2.5382 million USD [1] - **Integrated Circuit Business**: Revenue of 254 million yuan and a net profit of 12 million yuan. The total chip shipment reached 125 million units, a year-on-year increase of 9.38%, with non-consumable chip revenue growing by 58.52% [2] - **General Consumables**: Revenue of 1.322 billion yuan and a net profit of 16 million yuan. The company is expanding its client base in overseas markets, contributing to future market share and profit growth [2] Strategic Developments - Nasda's subsidiary, Gezhige, has formed a strategic partnership with JD.com to enhance its service capabilities in government and enterprise procurement [2] - The company is actively involved in the robotics sector, providing ultrasonic radar technology for Utree Technology and has been recognized for its innovative products in the robotics industry [3] - Continuous innovation investments and adjustments in the international market are expected to create growth opportunities in upcoming quarters [3]

证券代码：301122 证券简称：采纳股份 采纳科技股份有限公司 投资者关系活动记录表 编号：2025-001 投资者关系活 动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 参与单位名称 及人员姓名 线上参与公司2024年度业绩说明会的投资者 时间 2025年04月30日 15:00-16:00 地点 价值在线（https://www.ir-online.cn/）网络互动 上市公司接待 人员姓名 董事长兼总经理：陆军先生 董事会秘书：陆维炜先生 财务负责人：查凌云女士 独立董事：刘斌先生 保荐代表人：钟祝可先生 投资者关系活 动主要内容介 绍 1.根据2024年第三季度报告，采纳股份主营收入同比下降16.14%，归 母净利润下滑38.02%，扣非净利润降幅更高达44.09%，请问2025年有什么 措施保持财务健康度与盈利能力的持续性？ 答:尊敬的投资者，您好！公司2024年度归母净利润同比下降，主要系 本期受美国FDA进口警示影响，部分产品销售不及预期，同时针对受到进口 警示影响的部分存货、应收款项等项目计提了相应的减值准备 ...

①半导体材料业务： 2024年，实现主营业务收入15.2亿元，同比增长77.40%，占公司总营业收入比例持续提升。各细分业务具体进展如下： CMP抛光垫业务：全年营收7.16亿元，同比增71.51%，单月销量于9月突破3万片，CMP抛光垫国产供应龙头地位持续巩固。抛光硬垫制程占比及客户范 围持续扩大，铜制程抛光硬垫产品取得突破，武汉本部抛光硬垫产线产能至2025年一季度末已提升至月产4万片左右；潜江工厂抛光软垫于8月份实现扭亏 为盈，转入持续盈利模式。 抛光液/清洗液业务：收入2.15亿元，同比增178.89%，多晶硅及氮化硅抛光液获千万元级订单。 半导体显示材料业务：YPI、PSPI、TFE-INK收入4.02亿元，同比增131%，是国内部分主流面板厂第一供应商，仙桃产业园1,000吨PSPI产线投产提升供应 能力，年产800吨YPI二期项目启动，计划2025年内完工试运行。公司PFAS Free PSPI、BPDL产品已完成性能优化、实验线验证阶段，并送样国内主流面 板厂客户G6代线验证。 高端晶圆光刻胶业务：2024年，公司浸没式ArF及KrF晶圆光刻胶产品首获国内主流晶圆厂客户订单。潜江一期年产30吨 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [6][14]. Core Insights - The company reported a revenue of 8.978 billion RMB for 2024, representing a year-on-year growth of 9.69%, and a net profit of 695 million RMB, up 19.81% [2]. - For Q1 2025, the company achieved a revenue of 2.605 billion RMB, a significant increase of 36.47%, with a net profit of 249 million RMB, also up 36.26% [2]. - The company is expected to benefit from dual growth drivers in the consumer goods and medical sectors [2]. Performance Analysis - The consumer goods segment showed strong growth, with Q4 2024 revenue reaching 2.908 billion RMB, a 33.72% increase [3]. - For 2024, the medical supplies and consumer goods segments generated revenues of 3.906 billion RMB and 4.991 billion RMB, growing by 1.14% and 17.09% respectively [3]. - Key product categories such as cotton soft towels and children's clothing saw revenue increases of 31.19% and 13.21% respectively [3]. Q1 2025 Development - In Q1 2025, the medical segment generated 1.25 billion RMB, a 46.3% increase, with core categories like surgical supplies and high-end dressings showing remarkable growth [4]. - The consumer segment achieved 1.34 billion RMB in revenue, up 28.8%, with the "Princess Nais" sanitary napkin leading the category with a 73.5% increase [4]. - E-commerce contributed 59.9% of total revenue, with rapid growth in supermarket channels, which saw a 70.9% year-on-year increase [4]. Profitability - The gross margin for 2024 and Q1 2025 was 48.46% and 47.32% respectively, with a slight improvement in Q1 2025 due to product mix optimization [5]. - The net profit margin remained stable at 7.75% for 2024 and improved to 9.54% in Q1 2025 [5]. - The company aims to enhance brand strength and operational efficiency while focusing on core product categories [5]. Earnings Forecast and Valuation - The company is projected to have EPS of 1.80, 2.12, and 2.54 RMB for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 27, 23, and 19 [6].

湖北鼎龙控股股份有限公司投资者关系活动记录表 编号：20250429 | ■特定对象调研 | □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | 活动类别 | □现场参观 | | | ■其他：年度及一季度投资者交流电话会议 | | | 2025 年 4 月 29 日上午 10:30~11:30：嘉实基金：曲海峰、赵宇；浦银安盛基 | | | 金：高翔；信达澳亚基金：朱然；圆信永丰基金：胡春霞；理成资产：吴圣 | | | 涛、周锐、卢超；睿郡资产：刘力、沈晓源；博时基金：曹芮；宏道投资： | | 参与单位名称 | 丁开盛；富国基金：林庆；国投瑞银基金：钟婷霞、马柯；常春藤资产：程 | | | 熙云；易同投资：朱龙洋、党开宇、张科兵；野村国际（香港）：樊杨； | | 及人员姓名 | SCHRODERS INVESTMENT：ZhengMaggie、LeeJack、YimChris、Amelia | | | Wong 等，共 237 名投资者及证券人员。 | | | 2025 年 4 月 29 日下午 14:00~15:00：南方 ...

资讯网披露的相关公告，感谢您的关注。 3.公司之后的盈利有什么增长点？ 证券代码：300847 证券简称：中船汉光 中船汉光科技股份有限公司投资者关系活动记录表 编号：2025-001 | | □特定对象调研 □分析师会议 □媒体采访 ✔业绩说明会 | | --- | --- | | 投资者关系活动类 | | | 别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称及人员 | 通过"全景·路演天下"（https://rs.p5w.net）参与公司 2024 | | 姓名 | 年度网上业绩说明会的投资者 | | 时间 | 2025 年 4 月 29 日(周二) 下午 15:00~17:00 | | 地点 | 公司通过 全 景 网 " 投 资 者 关 系 互 动 平 台 " | | | （https://ir.p5w.net）采用网络远程的方式召开业绩说 | | | 明会 | | | 1．董事长黄立新 | | | 2．总经理苏电礼 | | 上市公司接待人员姓 | 3．财务总监李欢 | | 名 | 4. 独立董事许江涛 | | | 5．董事会秘书兼副总经理王冬雪 | | ...